Growth, Innovation, and Approval
PetVivo Reports Strong Fiscal 2026 Results, Launches AgenticPet AI Platform, and Gains Spryng® Authorization
PetVivo Holdings (OTCQX: PETV) reported its full-year Fiscal 2026 results on June 29, marking what the company called a turning point in its shift from a medical device maker to a tech-enabled animal health platform. The headline news: Health Canada officially authorized Spryng® with OsteoCushion® Technology as a veterinary medical device, opening the Canadian market for commercial launch, according to GlobeNewswire.
The same day, PetVivo launched public beta access to AgenticPet, its AI-powered platform for pet owners. The platform onboarded over 1,000 active users in its first 72 hours, GlobeNewswire reported. CEO John Lai called the Canadian authorization a key milestone, saying the company sees "a huge opportunity in Canada."
Health Canada Clears Spryng® for Canadian Commercialization
Spryng® with OsteoCushion® Technology is an injectable treatment for joint pain in animals. It uses sterilized extracellular matrix microparticles — tiny biological particles that cushion and support damaged joints. PetVivo markets it as a veterinary medical device, not a drug. That distinction matters: devices face fewer regulatory hurdles than pharmaceuticals, allowing faster paths to revenue, according to ADVFN.
The Health Canada authorization covers equines and companion animals. PetVivo plans a commercial launch in Canada in July 2026. The company also views this approval as a template for entering the European Union and United Kingdom markets later in 2026 and into 2027, according to GlobeNewswire.
AgenticPet AI Platform Targets an $140 Billion Market Gap
PetVivo's AgenticPet platform is an AI tool designed to educate pet owners and connect them to veterinary care. Digital Landia CEO Karim Quazzani, PetVivo's AI technology partner, said the rapid adoption "validates our core thesis" and pointed to "a $140 billion market gap between reactive vet visits and proactive daily monitoring," according to ADVFN.
The AI system claims 97% accuracy in spotting conditions like osteoarthritis by analyzing pet medical records. Beta veterinarians using the platform reported a 50% to 90% drop in client acquisition costs, bringing costs down to under $43 per customer. The platform targets gross margins of 80% to 90%, making it far more profitable than device sales alone, according to GlobeNewswire.
Revenue Growth and a Broadening Clinic Network
PetVivo posted a 51% revenue increase to $303,000 in its second fiscal quarter of 2026 compared to the same period a year earlier. The company also holds a partnership with Veterinary Growth Partners, which gives it access to over 7,300 U.S. veterinary clinics. That network is a key distribution channel for both Spryng® and the planned B2B veterinary AI platform, according to GlobeNewswire.
PetVivo holds 12 patents and 6 trade secrets covering its core technology. The AgenticPet B2C launch is designed to feed pet owners into the company's coming B2B veterinary platform, reducing marketing costs by building brand awareness directly with consumers first, according to ADVFN.
Analysts Flag Execution Risks Amid Positive Momentum
Market sentiment following the report was rated "Very Positive" by Rhea-AI analysis, with the Health Canada milestone seen as a major de-risking event. Still, analysts noted that the Canadian commercial launch and a pending acquisition of PiezoBioMembrane both remain unfinished. The acquisition is still subject to financing and due diligence, representing a real execution risk, according to Market Screener.
Some investor-focused coverage also highlighted the platform's Web3 and tokenization angles, which may appeal to tech investors but could raise skepticism among traditional veterinary practitioners focused on clinical outcomes. PetVivo CEO John Lai and CFO Garry Lowenthal held a conference call at 5:00 PM ET on June 29 to walk investors through the full-year performance, according to ADVFN.
Sentiment
NeutralPublishers
4
Articles
4
Reach
4
